147 related articles for article (PubMed ID: 6096752)
1. Effects of alpha-flupenthixol and naloxone on CRF-induced locomotor activation.
Koob GF; Swerdlow N; Seeligson M; Eaves M; Sutton R; Rivier J; Vale W
Neuroendocrinology; 1984 Nov; 39(5):459-64. PubMed ID: 6096752
[TBL] [Abstract][Full Text] [Related]
2. Stimulant and anxiogenic effects of corticotropin releasing factor.
Koob GF; Thatcher-Britton K
Prog Clin Biol Res; 1985; 192():499-506. PubMed ID: 3878524
[TBL] [Abstract][Full Text] [Related]
3. Corticotropin-releasing factor and behavior.
Koob GF; Bloom FE
Fed Proc; 1985 Jan; 44(1 Pt 2):259-63. PubMed ID: 3871412
[TBL] [Abstract][Full Text] [Related]
4. Alpha-flupenthixol-induced hyperactivity by chronic dosing in rats.
Sahakian BJ; Robbins TW; Iversen SD
Eur J Pharmacol; 1976 May; 37(1):169-78. PubMed ID: 945170
[TBL] [Abstract][Full Text] [Related]
5. Effects of corticotropin-releasing factor (CRF) and opiates on amphibian locomotion.
Lowry CA; Deviche P; Moore FL
Brain Res; 1990 Apr; 513(1):94-100. PubMed ID: 2161698
[TBL] [Abstract][Full Text] [Related]
6. Critical role of endogenous corticotropin-releasing factor (CRF) in the mediation of the behavioral action of cocaine in rats.
Sarnyai Z; Höhn J; Szabó G; Penke B
Life Sci; 1992; 51(26):2019-24. PubMed ID: 1335535
[TBL] [Abstract][Full Text] [Related]
7. Differences in sensitivity to neuroleptic blockade: medial forebrain bundle versus frontal cortex self-stimulation.
Corbett D
Behav Brain Res; 1990 Jan; 36(1-2):91-6. PubMed ID: 2302325
[TBL] [Abstract][Full Text] [Related]
8. Separate neural substrates of the locomotor-activating properties of amphetamine, heroin, caffeine and corticotropin releasing factor (CRF) in the rat.
Swerdlow NR; Koob GF
Pharmacol Biochem Behav; 1985 Aug; 23(2):303-7. PubMed ID: 3877311
[TBL] [Abstract][Full Text] [Related]
9. Involvement of spinal kappa opioid receptors in the antinociception produced by intrathecally administered corticotropin-releasing factor in mice.
Song ZH; Takemori AE
J Pharmacol Exp Ther; 1990 Aug; 254(2):363-8. PubMed ID: 2166788
[TBL] [Abstract][Full Text] [Related]
10. Chronic flupentixol treatment potentiates the reinforcing properties of systemic heroin administration.
Stinus L; Nadaud D; Deminière JM; Jauregui J; Hand TT; Le Moal M
Biol Psychiatry; 1989 Aug; 26(4):363-71. PubMed ID: 2765599
[TBL] [Abstract][Full Text] [Related]
11. Blockade of dopamine receptors in the renal vasculature by isomers of flupenthixol and sulpiride.
Schmidt M; Imbs JL; Giesen EM; Schwartz J
J Cardiovasc Pharmacol; 1983; 5(1):86-9. PubMed ID: 6186865
[TBL] [Abstract][Full Text] [Related]
12. alpha-Flupenthixol increases slow-wave in rats: effect of dopamine receptor blockade.
Fornal C; Wojcik WJ; Radulovacki M
Neuropharmacology; 1982 Apr; 21(4):323-5. PubMed ID: 7201087
[TBL] [Abstract][Full Text] [Related]
13. Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats.
Ehlers CL; Henriksen SJ; Wang M; Rivier J; Vale W; Bloom FE
Brain Res; 1983 Nov; 278(1-2):332-6. PubMed ID: 6605787
[TBL] [Abstract][Full Text] [Related]
14. Effects of corticotropin releasing factor on locomotor activity in hypophysectomized rats.
Eaves M; Thatcher-Britton K; Rivier J; Vale W; Koob GF
Peptides; 1985; 6(5):923-6. PubMed ID: 3878503
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of the consummatory, motivational and anticipatory aspects of feeding behavior by dopaminergic and opioidergic drugs.
Barbano MF; Cador M
Neuropsychopharmacology; 2006 Jul; 31(7):1371-81. PubMed ID: 16205784
[TBL] [Abstract][Full Text] [Related]
16. Different epileptogenic activities of murine and ovine corticotropin-releasing factor.
Marrosu F; Mereu G; Fratta W; Carcangiu P; Camarri F; Gessa GL
Brain Res; 1987 Apr; 408(1-2):394-8. PubMed ID: 3496140
[TBL] [Abstract][Full Text] [Related]
17. Behavioral activation by CRF: evidence for the involvement of the ventral forebrain.
Tazi A; Swerdlow NR; LeMoal M; Rivier J; Vale W; Koob GF
Life Sci; 1987 Jul; 41(1):41-9. PubMed ID: 3496511
[TBL] [Abstract][Full Text] [Related]
18. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor.
Izzo E; Sanna PP; Koob GF
Pharmacol Biochem Behav; 2005 Aug; 81(4):701-8. PubMed ID: 16005056
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory influence of corticotropin releasing factor on components of sexual behaviour in the male rat.
Sirinathsinghji DJ
Brain Res; 1987 Mar; 407(1):185-90. PubMed ID: 3495317
[TBL] [Abstract][Full Text] [Related]
20. Neurochemical and behavioral effects of corticotropin-releasing factor in the ventral tegmental area of the rat.
Kalivas PW; Duffy P; Latimer LG
J Pharmacol Exp Ther; 1987 Sep; 242(3):757-63. PubMed ID: 3498816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
